Skip to navigationSkip to content

How psychedelics became a pharma darling

Illustration by Jess Ebsworth
  • Alexandra Ossola
By Alexandra Ossola

Membership editor


There’s a room at a clinic in San Francisco, California that seems particularly well guarded. To get into it from outside, you have to open three locks. The building is outfitted with alarms and cameras. Inside, there’s a substance that dozens of companies are betting will be a major frontier in medicine.

The room houses MDMA, a drug known recreationally as ecstasy or molly. It’s being administered legally, under guidance from the Drug Enforcement Administration, as part of a clinical trial.

A burgeoning community of startups and investors hopes to capitalize on the results of trials like this one to usher in a new wave of psychedelic medicine. They’re vying to create the compounds and protocols that could be among the first to be approved for medical use.

Enrich your perspective. Embolden your work. Become a Quartz member.

Your membership supports our mission to make business better as our team of journalists provide insightful analysis of the global economy and helps you discover new approaches to business. Unlock this story and all of Quartz today.

Membership includes:

Quartz Japanへの登録をご希望の方はこちらから。